Breaking News, Collaborations & Alliances

South Korea’s ENCell Enters Japan CGT Market with CRC MOU

Signs an MOU with Cell Resources Corporation (CRC) designed to drive its expansion into the CGT market.

Author Image

By: Charlie Sternberg

Associate Editor

ENCell CEO Jang Jong-wook (left) and CRC CEO Arita Kotaro (right) sign a Memorandum of Understanding on March 4th. (Photo: ENCell Co., Ltd.)

ENCell Co., Ltd., a South Korean biotech specializing in advanced biopharmaceutical contract development and manufacturing organizations (CDMO) and novel drug development, has signed an MOU for collaboration in the field of CGT with Cell Resources Corporation (CRC) designed to drive the group’s expansion into the CGT market. CRC signed this MOU based on the belief that ENCell’s expertise in GMP operations and production technology would be beneficial to its CGT CDMO operations in Japan. EN...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters